---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-004576"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:15:57.210398+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics updates corporate presentation on bi-functional ADC pipeline

## Summary
- Updated slide deck highlights next-generation precision bi-functional antibody drug conjugate platform.
- Presentation dated January 2025 to be used in meetings with investors and potential partners.
- No new financial guidance, clinical data, or operational milestones disclosed in the filing.

## SEC filing metadata
- accession: 0000950170-25-004576
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017025004576/0000950170-25-004576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017025004576/aktx-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-004576
- JSON: https://secwatch.observer/filing/0000950170-25-004576.json
- Plain text: https://secwatch.observer/filing/0000950170-25-004576.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.